$HLYK

HealthLynked Corp

CIK:0001680139|SEC Filings

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Revenue
Total revenue	$ 249,830	$ 592,360	$ 673,295	$ 1,366,568
Operating Expenses and Costs
Practice salaries and benefits	139,223	285,379	281,327	687,745
Other practice operating expenses	122,185	247,395	222,004	561,371
Cost of product revenue	(520)	15,978	8,514	33,794
Selling, general and administrative expenses	517,489	451,755	1,364,770	1,081,170
Depreciation	10,229	27,238	36,269	55,262
Total Operating Expenses and Costs	788,606	1,027,745	1,912,884	2,419,342
Loss from operations	(538,776)	(435,385)	(1,239,589)	(1,052,774)
Other Income (Expenses)
Gain on extinguishment of debt		132,246	1,328,069	174,972
Loss on change in fair value of debt	(143,123)	(105,502)	(2,323,649)	(154,688)
Gain on change in fair value of derivative financial instruments	32,599	694	64,768	45,732
Amortization of original issue discounts on notes payable	(150,954)	(214,580)	(238,938)	(619,693)
Interest expense and other	(19,451)	(78,511)	(31,670)	(145,526)
Total other income (expenses)	(280,929)	(265,653)	(1,201,420)	(699,203)
Loss before provision for income taxes	(819,705)	(701,038)	(2,441,009)	(1,751,977)
Provision for income taxes
Net loss	(819,705)	(701,038)	(2,441,009)	(1,751,977)
Deemed dividend			(36,347)
Net loss to common shareholders	$ (819,705)	$ (701,038)	$ (2,477,356)	$ (1,751,977)
Net loss per share, basic and diluted:
Basic (in Dollars per share)	$ (0.28)	$ (0.25)	$ (0.84)	$ (0.62)
Fully diluted (in Dollars per share)	(0.28)	(0.25)	(0.84)	(0.62)
Net loss to common shareholders per share, basic and diluted:
Basic (in Dollars per share)	(0.28)	(0.25)	(0.85)	(0.62)
Fully diluted (in Dollars per share)	$ (0.28)	$ (0.25)	$ (0.85)	$ (0.62)
Weighted average number of common shares:
Basic (in Shares)	2,942,170	2,819,472	2,922,186	2,819,472
Fully diluted (in Shares)	2,942,170	2,819,472	2,922,186	2,819,472
Patient service revenue, net
Revenue
Total revenue	$ 230,515	$ 572,840	$ 649,128	$ 1,324,855
Subscription revenue
Revenue
Total revenue	7,187	7,099	10,681	16,683
Product revenue
Revenue
Total revenue	$ 12,128	$ 12,421	$ 13,486	$ 25,030

Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash Flows from Operating Activities
Net loss	$ (2,441,009)	$ (1,751,977)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	36,269	55,262
Stock based compensation, including amortization of deferred equity compensation	385,759	12,392
Gain on change in fair value of derivative financial instruments	(64,768)	(45,732)
Amortization of debt discount	238,938	619,693
Gain on extinguishment of debt	(1,328,069)	(174,972)
Loss on change in fair value of debt	2,323,649	154,688
Changes in operating assets and liabilities:
Inventory	(339)	17,098
Contract assets		9,381
Prepaid expenses and other current assets	(17,241)	29,461
Right of use lease assets	55,497	122,121
Accounts payable and accrued expenses	292,260	302,982
Lease liability	(55,497)	(123,153)
Contract liabilities	2,442	(77,333)
Net cash used in operating activities	(572,109)	(850,089)
Cash Flows from Investing Activities
Net cash used in investing activities
Cash Flows from Financing Activities
Proceeds from sale of common stock		10,000
Proceeds from related party notes payable and advances	515,000	710,000
Proceeds from third party notes payable and advances	500,000	305,000
Repayment of related party notes payable and advances	(39,840)
Repayment of third party notes payable	(427,343)	(230,951)
Net cash provided by financing activities	547,817	794,049
Net decrease in cash	(24,292)	(56,040)
Cash, beginning of period	37,136	76,241
Cash, end of period	12,844	20,201
Supplemental disclosure of cash flow information:
Cash paid during the period for interest	10,232	13,158
Cash paid during the period for income tax
Schedule of non-cash investing and financing activities:
Recognition of operating lease: right of use asset and lease liability		29,997
Extinguishment of operating lease: right of use asset and lease liability	(10,878)	(115,172)
Fair value of warrants allocated to proceeds of related party notes payable	9,699
Fair value of warrants allocated to proceeds of third party notes payable	54,135
Fair value of derivative financial instruments allocated to proceeds of third party notes payable	64,585	62,017
Fair value of beneficial conversion feature allocated to proceeds of related party notes payable		58,724
Original issue discounts allocated to proceeds of notes payable	140,843	113,002
Fair value of warrants issued to extend related party debt		47,751
Principal amount of convertible notes payable to related party refinanced	4,338,192	2,981,500
Deferred compensation payable included in principal balance of notes payable to related party	300,600
Principal amount of undocumented advances converted to convertible note payable to related party	269,840	420,000
Accrued interest included in fair value of note payable	42,509	234,329
Accounts payable included in principal balance of notes payable to related party		27,692
Incremental fair value of convertible note payable to related party resulting from refinancing	1,328,069	11,607
Fair value of shares issued for equity issuance costs		6,000
Deemed dividend resulting from down round adjustment	36,347
Issuance of previously subscribed shares	$ 11,851

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2026	Dec. 31, 2025
Current Assets
Cash	$ 12,844	$ 37,136
Inventory, net	18,300	17,962
Prepaid expenses and other current assets	50,176	32,935
Contingent sale consideration receivable	1,463,518	1,463,518
Total Current Assets	1,544,838	1,551,551
Property and equipment, net of accumulated depreciation of $764,979 and $728,710 as of June 30, 2026 and December 31, 2025, respectively	38,437	74,705
Right of use lease assets	9,715	76,090
Total Assets	1,592,990	1,702,346
Current Liabilities
Accounts payable, accrued expenses and other current liabilities	1,071,233	821,480
Contract liabilities	28,366	25,924
Lease liability, current portion	9,715	75,168
Derivative financial instruments	23,663	23,846
Notes payable, current portion, net of unamortized discounts of $134,091 and $109,027 as of June 30, 2026 and December 31, 2025, respectively	578,088	389,652
Indemnification liability	143,974	143,974
Total Current Liabilities	8,896,257	7,013,275
Long-Term Liabilities
Lease liability, long term portion		922
Government and other notes payable, long term portion	450,000	450,000
Total Liabilities	9,346,257	7,464,197
Commitments and contingencies (Note 14)
Shareholders’ Deficit
Common stock, par value $0.0001 per share, 500,000,000 shares authorized, 2,953,225 and 2,881,104 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively	295	288
Series B convertible preferred stock, par value $0.001 per share, 20,000,000 shares authorized, 2,750,000 and 2,750,000 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively	2,750	2,750
Common stock issuable, $0.0001 par value; 132,597 and 22,052 as of June 30, 2026 and December 31, 2025, respectively	49,510	61,349
Additional paid-in capital	45,210,752	44,712,980
Accumulated deficit	(53,016,574)	(50,539,218)
Total Shareholders’ Deficit	(7,753,267)	(5,761,851)
Total Liabilities and Shareholders’ Deficit	1,592,990	1,702,346
Related Party
Current Liabilities
Notes payable and other amounts due to related party, net of unamortized discounts of $5,261 and $-0- as of June 30, 2026 and December 31, 2025, respectively	$ 7,041,218	$ 5,533,231